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ABSTRACT
Objective To evaluate the effectiveness of offering
antenatal screening for sickle cell disease and
thalassaemia in primary care as a way of facilitating
earlier uptake of screening.
Design Partial factorial cluster randomised controlled
trial.
Setting 25 UK general practices from deprived inner city
areas.
Participants Anonymised data on all pregnant women
attending participating practices during a six month
period before randomisation and a seven month period
after randomisation. This included 1708 eligible women.
Intervention Practices were randomised to three groups
for seven months: parallel testing in general practice
(tests for sickle cell disease and thalassaemia offered to
both parents when pregnancy was first reported);
sequential testing in general practice (tests offered to
mothers when pregnancy was first reported, and
subsequently to the partners of womenwhowere found to
be carriers); and midwife care (tests offered to mothers at
first consultation with a midwife).
Main outcome measures The primary outcome (available
for all women) was the proportion of eligible women
screened before 10 weeks’ (70 days’) gestation.
Secondary outcomes were an offer of screening to women
before 10 weeks’ gestation, gestational age at testing,
mean interval from first visit to the general practice visit to
screening, andwomen’s knowledge of the carrier status of
their baby’s father before 77 days’ (11 weeks’) gestation.
The study was designed to detect a 20% absolute
increase in screening uptake. Cluster level analyses were
adjusted for age group, parity, ethnic group, primary care
organisation, and number of general practitioners per
practice.
Results Data were analysed for 1708 eligible women. In
the midwife care arm, 2% (9/441) of women were
screened before 10 weeks’ gestation compared with 24%
(161/677) in the GP parallel testing arm and 28% (167/
590) in the GP sequential testing arm. The estimated
adjusted difference between the midwife care and GP
parallel testing armswas 16.5% (95% confidence interval
7.1% to 25.8%; P=0.002) and between the midwife care
and GP sequential testing arms was 27.8% (14.8% to
40.7%; P<0.001). By 26weeks’ gestation theproportion of
women screened across the three trial arms was similar
(81%). The proportion of women who knew the carrier
status of the baby’s father by 11 weeks’ gestation was 0%
(0/441) in the midwife care arm, 2% (13/677) in the GP
parallel testing arm (P=0.003), and 1% (3/590) in the GP
sequential testing arm (P=0.374).
Conclusion Offering antenatal screening for sickle cell
disease and thalassaemia as part of consultations for
pregnancy confirmation in primary care increases the
proportion of women screened before 10 weeks’
gestation. Even with intervention, however, only a
minority of women were screened before 10 weeks.
Additional interventions should be considered to achieve
testing early in pregnancy for most women wanting such
tests so that couples with affected pregnancies have less
time pressure to choose options, which may include
termination of the pregnancy.
Trial registration Current Controlled Trials
ISRCTN00677850.
INTRODUCTION
Inherited disorders of haemoglobin are autosomal
recessive traits and include sickle cell disorders and
thalassaemia. These are the most common conditions
caused by single gene defects, with 5% of the world’s
population being carriers and about 300 000 births
worldwide affected by severe forms of the disease each
year.1 Northern and western Europe now have more
affected conceptions than southern Europe as a result
of recent migrations.2 The 59th World Health Assem-
bly recently urged member states to implement
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equitable and effective programmes for the prevention
and management of sickle cell anaemia.3 Policy
options for antenatal screening for sickle cell disease
and thalassaemia concern solely the offer of reproduc-
tive choice in the absence of early treatment to improve
outcomes. Policy options in the United Kingdom have
been evaluated in two systematic reviews.4 5 The results
of these reviews informed the introduction in England
of a universal antenatal screening policy in areas of
high prevalence in 2004. This policy has a target of
offering antenatal screening for sickle cell disease and
thalassaemia by 10weeks’ gestation to enable the com-
pletion of prenatal diagnostic testing by 13 weeks for
those who want it.6 The rationale for this is based on
evidence from two studies.7 8 Both showed an associa-
tion between gestational age and uptake of prenatal
diagnosis for haemoglobinopathy: women in earlier
stages of pregnancy were more likely to take up the
offer of prenatal diagnosis. It is postulated that by offer-
ing prenatal diagnosis sufficiently early in pregnancy,
women can have time to make an informed, less time
pressured decision about their options, which might
include termination.
A recent study provided the first population based
estimate of gestational age at screening for sickle cell
disease and thalassaemia. The results showed thatmost
women present to their family doctors early in preg-
nancy but that delays before screening are long. On
average, women attended their general practice to con-
firm their pregnancies at 7.6 weeks’ gestation (75% by
10 weeks). The median gestational age at testing, how-
ever, was 15.3 weeks, a median delay of 6.9 weeks.9
The proportion of women screened by 10 weeks was
4.4%. Evidence from two descriptive studies suggests
that the early offer of testing is associated with earlier
testing.10 11 Current practice is to offer sequential test-
ing to fathers: fathers are offered carrier testing only
when the mother has been identified as a carrier. This
policy has the potential to delay the assessment of the
carrier status of couples during pregnancy and hence
impact on risk to the fetus.
We investigated the utility of offering tests to both
parents simultaneously to reduce the delay in assessing
the carrier status of couples. Our objectives were two-
fold: to assess whether offering antenatal screening for
sickle cell disease and thalassaemia at the first visit for
confirmation of pregnancy in primary care leads to
earlier testing, and to assess whether indirectly offering
testing to fathers at the same time leads to earlier
knowledge of the couples’ carrier status.12
METHODS
The trial took place in two UK primary care trusts con-
taining 123 general practices. The two primary care
trusts are ranked among the most deprived in England
(sixth and 13th out of 354), with about 40% of their
populations being classified as representing ethnic min-
ority groups.13 An estimated 6%of the pregnantwomen
in the study areas carry a significant haemoglobin
variant.14 Women who become pregnant usually first
report their pregnancy to the general practice through
a consultation with the family doctor (the pregnancy
confirmationvisit). Thewomenare then referred to spe-
cialistmaternity services and receive a consultationwith
a midwife (the booking visit). This visit may take place
in a community setting. Other models of care, such as
direct access to midwifery led care, do occur, but none
of the women used this model of care during the trial
period. A universal screening policy was operating in
the study’s general practices—that is, all pregnant
womenwere offered testing for haemoglobin disorders.
We used a cluster randomised controlled design,
with general practice as the unit of randomisation,
firstly, to assess the effectiveness of three methods for
offering universal antenatal screening for sickle cell
disease and thalassaemia (box) and, secondly, because
it would be difficult to arrange for pregnant women
attending the same practice to receive differentmodels
of care.One of the interventions,midwife care, was the
standard pattern of care in the United Kingdom at the
time of the trial.
Recruitment and randomisation
We sent each of the 123 general practices a written
invitation to take part in a trial examining the feasibil-
ity, effectiveness, and acceptability of offering antena-
tal screening for sickle cell disease and thalassaemia in
primary care. The methods used to recruit and retain
practices in the trial are described elsewhere.15 Twenty
nine practices expressed an interest in the trial and 27
agreed to participate. Two practices withdrew before
randomisation.
Participating practices were allocated to inter-
vention groups after they had entered the run-in period
for data collection.Datawere collected at each practice
during this period for a minimum of six months to
obtain information on at least 33 pregnancies. The
run-in period varied between six and 11 months. The
trial statistician (MG) independently determined to
which intervention the 27practiceswould be allocated,
usingminimisation,16 stratifying for primary care trusts
and number of partners at the practice (1 or 2, ≥3). The
trialmanager (ED) informed theparticipatingpractices
of the group to which they had been allocated.
Participants
We collected anonymised data on all pregnant women
attending the participating practices during a six
Interventions to offer antenatal screening for sickle cell disease and thalassaemia
Parallel testing in general practice
Women were offered screening when they first reported their pregnancy in primary care.
Fathers were offered screening at the same time
Sequential testing in general practice
Women were offered screening when they first reported their pregnancy in primary care.
Fathers were offered screening only if the mother was identified as a carrier
Midwife care
Women were offered screening by the midwife at the booking visit. Fathers were offered
screening only if the mother was identified as a carrier
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month period before randomisation and a seven
month period after randomisation. Data were also col-
lected for screening outcomes until 26 weeks’ gesta-
tion. Women were eligible for inclusion in the
analysis if they wanted to continue their pregnancies,
their pregnancies were less than or equal to 19 weeks
and six days’ gestation at their first visit to primary
care, there was no written record of their sickle cell
and thalassaemia carrier status in primary care, and
their estimates of gestational age based on the date of
their last menstrual period were considered by them to
be certain.
We excluded women who confirmed their pregnan-
cies at later gestations because of the difficulties with
arranging a termination of pregnancy. All women,
regardless of ethnicity, were offered screening and
were eligible for the trial. All fathers of eligible preg-
nancies in practices allocated to the parallel testing
group were eligible to be offered the test at the same
time as the women. Likely response rates for fathers
were estimated from previous studies offering genetic
tests in primary care.17 A CONSORT diagram show-
ing the flow of practices and participants through the
trial is given in fig 1.
Measures
The primary outcome was uptake of screening by
women before 10 weeks’ (70 days’) gestation. Gesta-
tional age at test uptake was calculated from the first
day of the last menstrual period to the date of venesec-
tion for antenatal screening for sickle cell disease and
thalassaemia. These data were collected anonymously
from practices and were available for all eligible preg-
nancies. Secondary outcomes were an offer of screen-
ing to women before 10 weeks’ gestation; gestational
age at testing, as calculated by time from the date of the
last menstrual period to screening; mean interval from
first visit to the general practice to screening; and
women’s knowledge of the carrier status of their
baby’s father by 11 weeks’ (77 days’) gestation. The
offer of screening for sequential testing and parallel
testing groupswas determined from the practices’ elec-
tronic records and formidwife care from the date of the
booking visit, as recalled by the women.
Sample size
We estimated that, as for a trial with two arms, we
required data on 264 women attending eight general
practices (33 women per practice) in each trial group
to give sufficient power to detect an absolute difference
of 20% in the proportion ofwomenundergoing screen-
ing by 10 weeks’ gestation in different trial arms,
assuming 90% power and 5% significance. Our initial
estimate, based on unpublished audit data from South
Thames Regional Health Authority, suggested that
30% of women were screened by 10 weeks’ gestation.
The data monitoring committee (see web extra on
bmj.com) reviewed the sample size calculation before
the start of the intervention phase of the study. A
revised estimatewas informedby data collected during
a cohort study, representing the run-in phase of the
trial, providing updated estimates for screening uptake
and the intraclass correlation coefficients for screening
uptake under usual care.9 The trial had sufficient power
to detect a differencebetween trial arms of 20%, assum-
ing a revised rate of 4.4% of women screened by
10 weeks’ gestation in the midwife care arm. Sample
size calculations assumed an intraclass correlation
coefficient of 0.03, based on a review of 31 studies in
primary care, in which 75% of such coefficients were
less than 0.032.18 Analysis of data from the run-in data
collection phase of the present trial produced an intra-
class correlation coefficient of 0.036 for all women and
0.068 for eligible women.9 Repeating the initial sample
size calculations using an intraclass correlation coeffi-
cient of 0.07 indicated that data were required from
1173 eligible women. Available informationwas insuf-
ficient for a sample size calculation on testing the
fathers.
Recruitment and training
The research team invited the practices to participate
using a research information sheet for practices.19
Expenses of about £3000 (€3600; $4700) were avail-
able for each practice.We used research activity agree-
ments, detailing a payment schedule based on
deliverables, to administer these payments.15
We offered general practitioners, nurse practi-
tioners, and practice nurses in the intervention prac-
tices an evidence based training package using clinical
scenarios.20 This training outlined the topics to be cov-
ered when offering the screening test. These included
that the test was optional, the purpose of the test, the
meaning of possible results, and subsequent options.
These are in line with the recommendations of the
UK National Screening Committee and with the stan-
dard training offered to midwives. Midwives in the
midwife care practices were given locally provided
standard training in offering the screening test. All
underwent training in the research protocol. General
practitioners offered the test during consultations at
which women first reported their pregnancies. For
women accepting offers, blood tests were ordered
separately from other routine antenatal blood tests.
General practitioners did not cover other aspects of
the routine booking in pregnancy.
Interventions
GP parallel testing
General practitioners, practice nurses, and nurse prac-
titioners offered screening to eligible women at their
first visit for pregnancy confirmation. A verbal expla-
nation supplemented bywritten information produced
by theNHS sickle cell and thalassaemia screening pro-
gramme was provided. If the father was present, the
test was also offered to him. If the father did not attend
or was not registered at the practice, women were
invited to offer the baby’s father testing using a take
home pack. The pack contained written information
on the test, information on several local test centres
(primary care, local hospital, sickle cell and thalassae-
mia centre) where the test could be done, and a request
RESEARCH
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form. The fathers’ samples were analysed as soon as
they were received by the laboratory.
GP sequential testing
General practitioners, practice nurses, and nurse prac-
titioners offered screening to eligible women at their
first visit for pregnancy confirmation. Fathers of the
babies in this study group were offered sequential test-
ing—that is, offered a test only if the mother was found
to be a carrier of sickle cell disease or thalassaemia.
Local counsellors in sickle cell disease offered testing
to fathers, in line with the National Health Service
sickle cell and thalassaemia screening programme.
Midwife care
Womenwere offered screening at the booking appoint-
ment. This appointment is the first antenatal check and
is usually carried out by a community midwife; in this
trial either at the woman’s home, in a community based
clinic, or at a hospital. The fathers of the babies in this
study group were offered sequential testing.
In all groups blood samples were taken according to
local protocols. For participants in the general practice
(parallel and sequential testing) groups, blood samples
were usually taken just for this test; for participants in
the midwife care group, blood samples were usually
taken as part of a set of routine blood tests.
Data collection
Datawere collectedduring the run-in periodbefore the
intervention phase for a minimum of six months, or
longer if necessary, so that data were collected on a
minimum of 33 eligible pregnancies per practice. The
intervention phase lasted for sevenmonths, or longer if
necessary, so that datawere collected on aminimumof
33 pregnancies per practice. Data collection for the
run-in and intervention phases took place between
June 2005 and August 2007.
Fidelity to the researchprotocolwas assessed by com-
paring maternity referrals with records of pregnancies
received by the research team. Fidelity to the clinical
protocol in the intervention groups was assessed by
comparing records of pregnancies received by the
research team with the practice records of women
offered testing in primary care. Discrepancies were dis-
cussed and resolved with participating practices. We
repeated data abstraction for a sample of the primary
outcome measures and found it to be reliable.
Statistical analysis
To estimate the difference between intervention
groups in proportions of women screened before
10 weeks’ gestation, we implemented a cluster level
analysis, using linear regression of the practice specific
proportions on intervention group. We used the
method of minimum variance weights to allow for
varying numbers of eligible women between
practices.21 Analyses were adjusted for the proportion
of eligible women screened before 10 weeks’ gestation
in the run-in period, the age group of eligible women at
the practice, the proportion that were primiparous, the
proportion in higher risk ethnic groups, the number of
partners at the practice (1 or 2, ≥3), and primary care
trust. Thus the primarymeasure of effect is the adjusted
difference in uptake of screening before 10 weeks’
gestation, between trial arms. Analyses are described
in more detail in a full trial report.20 Individual level
analyses to estimate odds ratios or mean differences
using the method of generalised estimating equations
gave consistent results and are also reported in the trial
report.20 Among 1708 eligible women, 1376 were
screened before 182 days’ (26 weeks’) gestation. We
sought screening records by 26 weeks for the remain-
ing 332 women, up to the end of the study, but none
were found.This included74womenwhohad left their
practices at an undetermined date.
Cluster level analyses were also implemented for the
mean gestational age at uptake of screening and mean
delay from pregnancy confirmation visit to uptake of
screening. We used exact logistic regression to com-
pare screening uptake by fathers because the numbers
of events were small.
The intraclass correlation coefficient of a binary out-
come is associated with prevalence. These correlations
estimated by analysis of variance for the proportion
screened before 10 weeks’ gestation were 0.038 for
midwife care, 0.061 for GP parallel testing, and 0.142
for GP sequential testing.
RESULTS
Four practices from the two primary care trusts did not
agree to randomisation, resulting in 119 eligible prac-
tices being invited to participate in the trial (fig 1).
Overall, 29 practices participated, two as pilot sites
and27 in the trial. Twopracticeswithdrewand25 com-
pleted the trial. Data from the run-in phase before the
interventions were implemented are described
elsewhere.9
In the intervention phase 2421 pregnancies were
identified across 25 practices, of which 1708 met the
eligibility criteria (table 1). The trial groups did not
differ in age, parity, or proportion of women confirm-
ing pregnancybefore 70 days. In all three groups (para-
llel testing, sequential testing, and midwife care), over
70% of women had confirmed their pregnancies in pri-
mary care before 10 weeks’ gestation. Ethnicity dif-
fered slightly among the trial arms, with a higher
proportion of South Asian and South East Asian
women in the GP sequential testing arm than the
other trial arms, and more African and African Carib-
bean women in the GP parallel testing arm than the
other trial arms. In the run-in phase, uptake of screen-
ing before 10 weeks’ gestation was highest (7%) in the
practices assigned toGPparallel testing comparedwith
4% for midwife care and 3% for GP sequential testing.
More women were screened before 10 weeks’ gesta-
tion in both of the general practice intervention groups
(parallel and sequential testing) than in the midwife
care group. In the midwife care group, 2% (9/441) of
womenwere screenedbefore 10weeks’ gestation com-
pared with 24% (161/677) in the GP parallel testing
group and 28% (167/590) in the GP sequential testing
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group (table 2 and fig 2). After adjusting for pre-inter-
vention screening performance, age, parity, and ethni-
city, compared with midwife care the uptake of
screening before 10 weeks’ gestation was 16.5% (95%
confidence interval 7.1% to 25.8%; P=0.002) for GP
parallel testing and 27.8% (14.8% to 40.7%; P<0.001)
forGP sequential testing (table 3).Although theuptake
of screening at 10weeks seemed to be slightly higher in
the sequential testing arm than in the parallel testing
arm, this was not maintained at later gestational ages
(fig 2). Adjustment for pre-intervention screening per-
formance was quantitatively more important in the
parallel testing group; nevertheless, uptake of screen-
ing in the two intervention arms was not significantly
different from each other at 10 weeks’ gestation
(P=0.119). Changes were considered across practices
and the results were not driven by any one practice.
Details of the trial outcomes for each general practice
are in the full report. 20
In the midwife care group, 3% (3/90) of women were
offered screening before 10 weeks’ gestation compared
with 47% (321/677) in theGPparallel testing group and
48% (281/590) in theGP sequential testing group. In the
adjusted analysis, the increases in proportion of partici-
pants offered the test before 10 weeks’ gestation com-
pared with midwife care was 39.2% (26.0% to 52.4%;
P<0.001) for GP parallel testing and 44.2% (26.6% to
61.9%; P<0.001) for GP sequential testing (table 2).
The mean gestational age at screening for women
with tests done in the midwife care group was
118 days compared with 94 days in the GP parallel
testing group and 90 days in the GP sequential testing
group. In the adjusted analysis, the differences com-
paredwithmidwife care were 15.5 days forGP parallel
testing (P=0.008) and 21.8 days for GP sequential test-
ing (P=0.003; table 3 and fig 2).
Themean interval between the pregnancy confirma-
tion visit and screeningwas 60 days in themidwife care
group. This delay was reduced by 18.0 days in the GP
parallel testing group and by 21.5 days in the GP
sequential testing group (table 3 and fig 2).
The overall pattern of uptake for screening was simi-
lar for GP sequential testing and GP parallel testing
groups (fig 2). Further analyses showed no differences
Practices in 2 primary care trusts (n=123)
Practices (n=119)
Practices who expressed an interest in participating (n=29)
Midwife care: test offered to mothers
by midwives then to partners
of mothers found to be carriers
General practice: parallel testing:
test offered to mothers
and fathers in primary care
General practice: sequential testing:
test offered to mothers in primary care then
to partners of mothers found to be carriers
Total pregnancies:
8 clusters provided anonymous
data on 619 pregnancies
Median (interquartile range)
cluster size 59.5 (49.5-114.0)
Total pregnancies:
8 clusters provided anonymous
data on 1010 pregnancies
Median (interquartile range)
cluster size 120.5 (86.0-156.5)
Total pregnancies:
9 clusters provided anonymous
data on 792 pregnancies
Median (interquartile range)
cluster size 81.0 (78.0-99.0)
Eligible pregnancies:
8 clusters provided anonymous
data on 677 pregnancies
Median (interquartile range)
cluster size 73.0 (61.5-109.5)
Eligible pregnancies:
9 clusters provided anonymous
data on 590 pregnancies
Median (interquartile range)
cluster size 64.0 (59.0-69.0)
Eligible pregnancies:
8 clusters provided anonymous
data on 441 pregnancies
Median (interquartile range)
cluster size 43.0 (36.0-76.0)
Ineligible pregnancies (n=178):
  Data on last menstrual period missing
    (n=10)
  Termination of pregnancy (n=37)
  Miscarried (n=48)
  Sickle cell and thalassaemia carrier
    status already known (n=47)
  >19 weeks and 6 days’ gestation at first
    visit to general practice (n=62)
Ineligible pregnancies (n=333):
  Data on last menstrual period missing
    (n=24)
  Termination of pregnancy (n=113)
  Miscarried (n=58)
  Sickle cell and thalassaemia carrier
    status already known (n=85)
  >19 weeks and 6 days’ gestation at first
    visit to general practice (n=105)
Ineligible pregnancies (n=202):
  Data on last menstrual period missing
    (n=16)
  Termination of pregnancy (n=51)
  Miscarried (n=32)
  Sickle cell and thalassaemia carrier
    status already known (n=57)
  >19 weeks and 6 days’ gestation at first
    visit to general practice (n=81)
Practices that did not agree to randomisation (n=4)
Practices randomly allocated to three groups (allocation stratified by primary care trust and practice size) (n=27)
Pilot practices, 1 from each primary care trust (n=2)
Practices (n=25)
Withdrawn practices (n=2)
Fig 1 | Flow of practices and participants through study
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between these groups for offer or uptake of screening
before 10 weeks’ gestation, gestational age at uptake of
screening, or delay between confirmation of preg-
nancy and screening. By 26 weeks’ gestation the pro-
portions of women screened across the three groups
were similar.Overall, 81%ofwomenwere screenedby
26 weeks’ gestation (table 2).
The uptake of screening by fathers was 8% (51/677)
in the GP parallel testing group, 3% (16/590) in the GP
sequential testing group, and 3% (13/441) in the mid-
wife care group. The proportion of women who knew
the carrier status of the baby’s father by 77 days’
(11 weeks’) gestation was 0% (0/441) in the midwife
care group, 2% (13/677) in the GP parallel testing
group (P=0.003), and 1% (3/590) in the GP sequential
testing group (P=0.374).
Overall uptake of screening before 26 weeks’ gesta-
tion was similar in northern Europeans and in women
of “higher risk” ethnicity. In adjusted analyses, ethni-
city was not associated with uptake of screening before
10 weeks’ gestation or 26 weeks’ gestation and mean
gestational age at the time of screening. In adjusted
analyses, however, women of higher risk ethnicity
had a shorter delay from the visits for pregnancy
confirmation to testing: the mean difference from
northern Europeans was about 7.4 days (95% confi-
dence interval 2.5 to 12.3).
Overall uptake of screening before 10 weeks’ gesta-
tion was 15% inwomen aged 24 years and younger but
21% in women aged more than 32 years. The mean
difference in gestational age at screening (adjusted for
trial arm, primary care trust, number of doctors at prac-
tice, parity, high risk ethnicity, and run-in screening
performance) between women aged 24 or less and
those aged more than 32 years was 11.3 days (6.2 to
16.4; P<0.001). This was associated with later visits
for pregnancy confirmation among the younger
mothers who, on average, confirmed their pregnancies
about 10 days later than older mothers. Screening out-
comeswere generally similar for primiparous andmul-
tiparous women.
No adverse events occurred in this trial.
DISCUSSION
Offering antenatal screening for sickle cell disease and
thalassaemia at a visit for confirmation of pregnancy in
primary care increased the proportion of women
screened before 10 weeks’ gestation. It also reduced
Table 1 | Characteristics of participants. Values are frequencies (percentage of eligible participants in group) unless stated otherwise
Characteristics Midwife care sequential
General practice
P value*Parallel testing Sequential testing
No of general practices 8 8 9 —
Primary care trust A: B 4:4 4:4 5:4 Stratifier
No of general practitioners at practice (1-2: ≥3) 3:5 3:5 3:6 Stratifier
Run-in phase: No of eligible participants 336 594 460 —
Pregnancy confirmation visit <10 weeks’ (70 days’) gestation 255 (76) 458 (77) 347 (75) 0.941
Screening test <10 weeks’ gestation 12 (4) 39 (7) 12 (3) 0.275
Mean (interquartile range) gestational age at screening (days) 111 (91-130) 104 (87-120) 110 (88-129) 0.318
Mean (interquartile range) duration from pregnancy confirmation to
screening (days)
53 (34-72) 48 (32-63) 49 (36-65) 0.460
Intervention phase
All participants† 619 1010 792 —
Eligible participants†‡ 441 (71) 677 (67) 590 (74) —
Median (interquartile range) age (years) 28.0 (23.6-32.8) 28.0 (23.9-32.2) 29.1 (25.2-33.8) 0.250
Primiparous 241 (55) 392 (58) 307 (52) 0.650
Pregnancy confirmation visit <10 weeks’ gestation 323 (73) 505 (75) 464 (79) 0.386
Ethnic group:
Northern European 76 (17) 101 (15) 121 (21)
0.001
South Asian and South East Asian 93 (21) 103 (15) 224 (38)
African and African Caribbean 84 (19) 180 (27) 93 (16)
Southern European and other European 70 (16) 138 (20) 72 (12)
Other ethnicity 14 (3) 25 (4) 22 (4)
Mixed ethnicity 12 (3) 13 (2) 13 (2)
Not known 92 (21) 117 (17) 45 (8)
Ineligible participants†:
Data on last menstrual period missing 10 24 16 —
Termination of pregnancy 37 113 51 —
Miscarriage 48 58 32 —
Carrier status known 47 85 57 —
First visit ≥140 days’ gestation 62 105 81 —
*Test for difference between groups.
†87 had two or more exclusion criteria.
‡Values are number (percentage of all participants).
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the delay between women presenting for pregnancy
and tests being offered and carried out. The offer did
not alter the overall proportion of women screened,
indicating that the different methods of offering the
test did not affect whether women underwent testing,
but the stage in pregnancy when they received the
offer. Offering testing to fathers at the pregnancy con-
firmation visit was associated with low uptake of
screening. Even after intervention, only a few women
were screened before 10 weeks’ gestation. It is not
known if the delay in screening in women allocated
to midwife care resulted from a delay in seeing a mid-
wife or if therewere additional delays between the con-
sultation and testing in that intervention arm.
Unanswered questions and future research
The level of screening uptake observed in this popula-
tion was lower than anticipated when the trial was
designed. This is partly explained by the exclusion of
women whose carrier status was already known. In
addition, substantial variations in uptake of screening
between family practices, ranging from 0% to 22%,
were observed in this study.20 Taking these two factors,
as well as sampling error, into account it is not surpris-
ing that an unpublished audit might generate a result
that differed from our population based estimates.
None the less, our findings serve to emphasise the
low levels of uptake for screening early in pregnancy
and the need for additional interventions to raise these
further. Development of suitable interventions may
require qualitative research to understand the reasons
why women attend early or not, as well as understand-
ing the organisational and professional barriers and
facilitators of early testing. Some studies suggest that
general practitioners attribute failure to test to lack of
time, language barriers, or lack of training.20When the
test was offered, the organisation of phlebotomy ser-
vices did not always facilitate same day testing. Devel-
opments in testing technology may allow the use of
blood spots for antenatal screening for sickle cell dis-
ease and thalassaemia,22 which may reduce the need
for phlebotomy services and thus reduce some of the
observed delay in testing.
The potential consequences of an earlier offer of
screening in terms of offering and carrying out subse-
quent invasive procedures earlier in pregnancy was
not evaluated in this trial because to do so would have
requireda larger sample size.This supposition therefore
requires investigation. Nor did this trial investigate the
views of women who may have undergone screening
knowing that theywouldnot terminate an affected fetus.
Reproductive choice includes options to decline or
accept prenatal diagnosis. Screening programmes
need to ensure that choices to decline and to accept
prenatal diagnosis aremade with appropriate informa-
tion and in line with individual attitudes. Uptake in the
absence of informed choice is an undesirable
outcome.23 Informed choice was assessed in this trial
and is reported separately.20 Although there were no
differences in rates of informed choice across the trial
groups, the overall rates of informed choice were low,
with about a third of women classified as making an
informed choice.
Table 2 | Screening outcomes by intervention group. Values are numbers (percentages) unless stated otherwise
Variables
No (%)
Midwife care
(n=441)
Parallel testing in
general practice (n=677)
Sequential testing in
general practice (n=590)
Women’s uptake of screening <10 weeks’ (70 days’) gestation 9 (2) 161 (24) 167 (28)
Offer of screening <10 weeks’ gestation 3/90* (3) 321 (47) 281 (48)
Mean (interquartile range) gestational age at screening uptake† (days) 118 (101-134) 94 (66-118) 90 (61-113)
Mean (interquartile range) interval from pregnancy confirmation visit to screening uptake (days) 60 (42-79) 35 (7-59) 31 (5-54)
Screening uptake of fathers 13 (3) 51 (8) 16 (3)
Women who knew carrier status of baby’s father by 11 weeks’ (77 days’) gestation 0 (0) 13 (2) 3 (1)
Women’s uptake of screening <26 weeks’ (182 days’) gestation 324 (73) 571 (84) 481 (82)
*Offer of test ascertained for 90 respondents only.22
†Women who were screened <26 weeks’ gestation.
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Fig 2 | Proportion of women screened by gestational age
according to intervention group (upper panel) and distribution
of pregnancy confirmation visits to general practices for all
groups combined (lower panel)
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Comparison with other studies
In a previous observational study in which antenatal
screening for sickle cell disease and thalassaemia was
offered in primary care, lower uptake of testing was
observed compared with uptake by women receiving
midwife care. This seemed to reflect failures within the
organisation and delivery of screening.11 Such failures
were avoided in the current trial: offering testing in
primary care did not alter the likelihood of testing in
this trial. This suggests that uptake of screening is not
influenced by offers early in pregnancy or by the pro-
fessional group offering the test.
We estimated, based on limited data, that there
would be a 20% increase in uptake of screening from
30% to 50%. In this study, baseline uptake of screening
was much lower than anticipated. However, the sam-
ple size was re-estimated and reviewed by the data
monitoring committee, based on a cohort study for
baseline in the same population, with data for some
1500 women. The trial provides data for a further
1700 women. We did not have confidence in the 30%
figure as indicated previously.
The trial found limited benefit from offering tests to
fathers at the same time as those to mothers, given few
fathers underwent testing. This is in contrast to the 90%
uptake of carrier testing of fathers for cystic fibrosis
observed in a similar trial in primary care.17 Several dif-
ferences between the trialsmay account for this contrast:
the current trial offered testing to the biological father
rather than to the woman’s partner and required blood
testing rather than a salivary sample. In the current trial
the biological father was not always registered at the
same general practice as the woman, or was unavailable
for other reasons. A further difference was that the cur-
rent trial was carried out in an area with high levels of
social andmaterial deprivation. Data were not recorded
on the number of fathers who attended primary care
with pregnant women. The testing of fathers required a
blood sample. Blood tests were offered to fathers in the
parallel testing group inoneof twoways inprimary care:
face to face when present at the consultation or, if not
present, with the assistance of the women, who were
given a pack containing information on screening and
how to access testing to give to the baby’s father. Uptake
of testing by fathers before 11 weeks’ gestation (51/677)
may seem low because uptake of maternal testing by
70 days was low (161/677).
Strengths and limitations of the study
The trial design was robust and the likelihood of bias
was low: allocation to trial arms was randomised, with
allocation concealed to participants before the inter-
vention and the primary end point was reported for
all participants. The trial was carried out in the United
Kingdom in areas with high prevalence of sickle cell
disease and thalassaemia. This raises questions about
the generalisability of the findings to other countries
and areas with lower prevalence and to screening for
other conditions. The extent to which the trial results
can be applied in other contexts will probably depend
on the existence and organisation of primary care ser-
vices. Further questions about the generalisability arise
as the outcomes were achieved under trial conditions:
the offer of screening was for a limited period and the
research team contacted practices on a regular basis to
encourage fidelity to the protocol.
The general practices observed were not randomly
selected from the 123 general practices in the two pri-
mary care trusts studied and therefore may not be
representative of the practices in these trusts. The vari-
ables on which data are available show that participat-
ing practiceswere similar to other practices in the study
primary care trusts for practice size, deprivation, and
patient ethnic group. In addition, the study primary
care trusts were chosen to represent geographical
areas with a high prevalence of sickle cell disease and
thalassaemia and therefore may not be representative
of other areas. The primary care trusts represent
deprived inner city areas where general practice lists
are longer than those in suburban or rural areas and
primary care services are generally less well
organised.20
The trial arms differed in more ways than just the
timing at which testing was offered. Those in the inter-
vention groups were trained by the research team
whereas those in the midwife care group were offered
locally provided standard training.20 Midwives pre-
sented the test in themidwife care group, whereas gen-
eral practitioners presented the test in the other two
groups. The similar rates of uptake of testing in the
three groups suggest, however, that any differences in
Table 3 | Adjusted cluster level analysis showing estimated effect of intervention on screening outcomes, with midwife care as reference group
Outcome
Parallel testing in general practice (n=677) Sequential testing in general practice (n=590)
Estimate (95% CI) P value Estimate (95% CI) P value
% increase in uptake of screening <10 weeks’ (70 days) gestation* 16.5 (7.12 to 25.8) 0.002 27.8 (14.8 to 40.7) <0.001
% increase in offer of screening <10 weeks’ gestation† 39.2 (26.0 to 52.4) <0.001 44.2 (26.6 to 61.9) <0.001
Mean reduction in days of gestational age at screening‡ −15.5 (−26.4 to −4.63) 0.008 −21.8 (−34.8 to −8.80) 0.003
Mean reduction in days from pregnancy confirmation to screening§ −18.0 (−26.3 to−9.7) <0.001 −21.5 (−32.5 to −10.4) 0.001
% increase in uptake of screening <26 weeks’ gestation¶ 3.80 (−7.93 to 15.54) 0.502 9.83 (−2.30 to 22.0) 0.105
*Adjusted for model 1 and proportion of women screened before 10 weeks’ gestation in run-in period.
†Adjusted for age group, parity, proportion of high risk ethnic groups, primary care trust, and number of doctors at practice (model 1).
‡Adjusted for model 1 and mean gestational age at screening in run-in period.
§Adjusted for model 1 and mean time interval from pregnancy confirmation to screening in run-in period.
¶Adjusted for model 1 and uptake of screening before 26 weeks’ gestation in run-in period.
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test presentation related to profession did not affect
uptake. Information on the screening test provided to
the pregnant women in all three trial groups was the
same—namely, literature on NHS screening
programmes.24 The number of carriers detected was
too small to evaluate effects on reproductive choices.
It is acknowledged that uptakeof testingby fathersmay
be associated with ethnicity, but this is unlikely to be
relevant in this trial because overall the uptake of test-
ing by fathers was low. The small number of fathers
tested raises questions about the generalisability of
the results of such testing.
The date of testing was not the same as the date
women were informed of their test results. The delay
between pregnancy confirmation and women being
informed of their test results is likely to be greater
than the delay between pregnancy confirmation and
testing.
The analysis had limitations: only a modest number
of practices participated, with small numbers of
women per practice, consequently limiting the ana-
lyses. We used a cluster level analysis of the practice
specific means and proportions to facilitate presenta-
tion of differences in proportions. Analyses were
weighted for varying cluster sizes using minimum var-
iances weights.20 This requires estimation of the intra-
class correlation coefficient (ρ) for each trial group.The
number of practices may not have been sufficient to
provide precise estimates of ρ. Differences in estimates
were, however, negligible and showed no difference in
interpretation from using analyses that were
unweighted or weighted for cluster size. We also car-
ried out analyses at individual level, using the method
of generalised estimating equations, incorporating
adjustments to allow for the small number of practices.
These results were consistent with the cluster level ana-
lyses. Since data for testing of fathers andmaternal car-
riers were sparse, we used exact logistic regression, but
analyses implemented using ordinary logistic regres-
sion with robust standard errors gave consistent
results.
As this was a three arm trial and the two intervention
groups, sequential testing and parallel testing, might
not have had truly independent effects, reported P
values should be interpreted cautiously. The analysis
plan did not, however, include adjustment of P values
for multiple testing.
Conclusions
The results of this trial suggest that offering testing to
women in primary care has some potential to increase
the uptake of screening in early pregnancy. Fully rea-
lising this potential requires three things; firstly, that
women need to report their pregnancies early; sec-
ondly, that women need to be offered screening early
in pregnancy; and thirdly, that the carrier status of cou-
ples needs to be confirmed within days of identifying
women carriers, in those who want to proceed with
further testing. Achieving this requires systems
designed to achieve timely, effective, and sensitively
delivered services. A potentially more effective way
to achieve early decision making is through precon-
ceptual screening.25
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